<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890747</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02208</org_study_id>
    <secondary_id>NCI-2012-02208</secondary_id>
    <secondary_id>AMC-061</secondary_id>
    <secondary_id>AMC-061</secondary_id>
    <secondary_id>U01CA121947</secondary_id>
    <nct_id>NCT00890747</nct_id>
    <nct_alias>NCT01727102</nct_alias>
  </id_info>
  <brief_title>Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy</brief_title>
  <official_title>A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of sunitinib malate in treating
      human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral
      therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and to investigate the pharmacological interactions of
      administering sunitinib (sunitinib malate) in subjects with cancer who are also HIV positive
      on anti-retroviral regimens containing protease inhibitors and/or non-nucleoside reverse
      transcriptase inhibitors.

      SECONDARY OBJECTIVES:

      I. To evaluate the efficacy of sunitinib in treating non-acquired immunodeficiency syndrome
      (AIDS) defining cancers (NADCs) in these subjects.

      II. To detect alterations in antiretroviral drug pharmacokinetics due to sunitinib.

      III. To detect alterations in immune parameters, including total leukocyte count, cluster of
      differentiation (CD) 4 and viral load, during sunitinib therapy.

      IV. To correlate variations in genes involved in sunitinib absorption, metabolism, and
      elimination, including cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4),
      cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5), ATP-binding cassette,
      sub-family B (MDR/TAP), member 1 (ABCB1), and breast cancer resistance protein (ABCG2), with
      drug pharmacokinetics.

      V. To explore the potential for pharmacological interactions between sunitinib and newer
      antiretroviral agents such as integrase and chemokine (C-C motif) receptor 5
      (gene/pseudogene) (CCR5) inhibitors.

      OUTLINE: This is a dose-escalation study.

      Patients receive sunitinib malate orally (PO) daily on days 1-28. Courses repeat every 6
      weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grades 3, 4, and 5, treatment-related adverse events, graded according to the National Cancer Institute (NCI) CTCAE version 3.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Results will be presented descriptively. Continuous data will be summarized for each cohort using descriptive statistics (N, mean, median, standard deviation, minimum, maximum, geometric mean, and % coefficient of variation [CV]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) defined as an adverse event that is possibly related to the study medication, graded according to the NCI CTCAE version 3.0</measure>
    <time_frame>6 weeks</time_frame>
    <description>Results will be presented descriptively. Continuous data will be summarized for each cohort using descriptive statistics (N, mean, median, standard deviation, minimum, maximum, geometric mean, and % coefficient of variation [CV]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of response</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (solid tumors), AIDS Clinical Trials Group (ACTG) (Kaposi's sarcoma [KS]), Cheson (lymphoma), Durie (multiple myeloma), or International Working Group for Response Criteria for acute leukemias criteria depending on the subject's primary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral drug pharmacokinetics due to sunitinib malate</measure>
    <time_frame>At baseline and at 1, 2, 3, 4, 5, 6, 7, 8, and 24 hours of days 1and 2</time_frame>
    <description>Pharmacokinetic parameters within the individual groups will be compared using a Kruskall-Wallis test, Wilcoxon non-parametric test for paired data and Mann-Whitney test for unpaired data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in immune parameters, including total leukocyte count, CD4, and viral load</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Adult Langerhans Cell Histiocytosis</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Aggressive NK-cell Leukemia</condition>
  <condition>AIDS-related Diffuse Large Cell Lymphoma</condition>
  <condition>AIDS-related Diffuse Mixed Cell Lymphoma</condition>
  <condition>AIDS-related Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>AIDS-related Immunoblastic Large Cell Lymphoma</condition>
  <condition>AIDS-related Lymphoblastic Lymphoma</condition>
  <condition>AIDS-related Malignancies</condition>
  <condition>AIDS-related Small Noncleaved Cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative</condition>
  <condition>Chronic Eosinophilic Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Neutrophilic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Extramedullary Plasmacytoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>HIV Infection</condition>
  <condition>HIV-associated Hodgkin Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Isolated Plasmacytoma of Bone</condition>
  <condition>Light Chain Deposition Disease</condition>
  <condition>Mast Cell Leukemia</condition>
  <condition>Myelodysplastic Syndrome With Isolated Del(5q)</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Myeloid/NK-cell Acute Leukemia</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncutaneous Extranodal Lymphoma</condition>
  <condition>Osteolytic Lesions of Multiple Myeloma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Progressive Hairy Cell Leukemia, Initial Treatment</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <condition>T-cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (sunitinib malate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sunitinib malate)</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sunitinib malate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sunitinib malate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven solid tumor or hematological malignancy, including:

               -  Metastatic renal cell carcinoma

               -  A solid tumor malignancy, including an NADC or an AIDS-defining malignancy, if
                  the subject has progressed following standard therapy and/or other curative
                  options are not available

               -  A hematologic malignancy, except for blast-phase leukemia, for which effective
                  standard therapy or other curative options are not available

          -  Serologic documentation of HIV infection at any time prior to study entry, as
             evidenced by positive enzyme linked immunosorbent assay (ELISA), positive western
             blotting (Western Blot), or other federally approved licensed HIV test, or a
             detectable blood level of HIV ribonucleic acid (RNA), or a positive anti-HIV antibody
             test

          -  On stable anti-retroviral therapy for at least 4 weeks with a protease inhibitor
             (PI)-based or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen of
             at least three drugs, with no intention to change the regimen within 8 weeks after
             starting study drug

               -  Patients who are on NNRTI and ritonavir PI-based therapy are eligible and will be
                  enrolled in the ritonavir PI-based group (Group 3)

               -  Patients who are on NNRTI and non-ritonavir PI-based therapy are eligible and
                  will be enrolled in the non-ritonavir PI-based group (Group 2); NOTE: accrual to
                  Group 2 will be closed upon approval of version 7.0 of the protocol

               -  Patients who are on a highly active antiretroviral therapy (HAART) combination
                  that includes neither a PI nor a NNRTI agent are eligible and will be enrolled in
                  the NNRTI-based group (Group 1)

          -  CD4 count &gt; 50 cells/uL

          -  Karnofsky performance status &gt; 60%

          -  Women of child-bearing potential must have a negative pregnancy test within 7 days
             before initiation of study drug dosing; post menopausal women must be amenorrheic for
             at least 12 months to be considered of non-childbearing potential; male and female
             subjects of reproductive potential must agree to employ an effective barrier method of
             birth control throughout the study and for up to 3 months following discontinuation of
             study drug; (Note: a woman of childbearing potential is one who is biologically
             capable of becoming pregnant; this includes women who are using contraceptives or
             whose sexual partners are either sterile or using contraceptives)

          -  Hemoglobin &gt;= 8.0 gm/dL

          -  Absolute neutrophil count (ANC) &gt;= 1500 cells/mm^3

          -  Platelet count &gt;= 100,000 /mm^3

          -  Creatinine within institutional normal limits or glomerular filtration rate (GFR) &gt; 60
             mL/min/m^2 (calculated by the Cockcroft-Gault equation), calculated as follows:

               -  For males = (140 - age[years]) x (body weight [kg])/ (72) x (serum creatinine
                  [mg/dL])

               -  For females = 0.85 x male value

          -  Total bilirubin should be =&lt; 1.5 times upper limit of normal (ULN); if, however, the
             elevated bilirubin is felt to be secondary to indinavir therapy, then subjects will be
             allowed on protocol if total bilirubin =&lt; 3.5 mg/dL, provided that the direct
             bilirubin is =&lt; 1.5 times ULN; if the elevated bilirubin is felt to be secondary to
             atazanavir therapy, then subjects will be allowed on protocol without any limit on the
             total bilirubin if the direct bilirubin is =&lt; 1.5 times ULN

          -  Aspartate transaminase AST (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase ALT (serum glutamate pyruvate transaminase [SGPT]) &lt; 2.5
             times the ULN; unless subjects have liver metastases, in which case both AST and ALT
             must be =&lt; 5 times ULN

          -  Life expectancy of 3 months or more

          -  Ability and willingness to give informed consent

          -  Subjects must in the opinion of the Investigator be capable of complying with this
             protocol

        Exclusion Criteria:

          -  Concurrent active opportunistic infection (OI)

          -  Acute treatment for an infection or other serious medical illness within 14 days prior
             to study entry

          -  Receipt of antineoplastic therapy, including investigational drug or standard
             treatment, within 2 weeks of study entry; must be able to demonstrate adequate
             recovery from prior therapy-related toxicities

          -  Major surgery or radiation within 3 weeks prior to study entry

          -  Concurrent treatment with medications, other than antiretroviral drugs used to treat
             HIV infection, that are known to inhibit or induce CYP3A4

          -  Gastrointestinal tract disease resulting in an inability to take oral medication or a
             requirement for intravenous (IV) alimentation, prior surgical procedures affecting
             absorption, or active peptic ulcer disease

          -  Clinically significant cardiovascular disease, including uncontrolled hypertension
             (diastolic blood pressure &gt;= 100 mmHg despite optimal medical therapy) or unstable
             angina

          -  A myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism
             within 6 months of study entry

          -  Abnormal left ventricular ejection fraction per institutional standards

          -  Ongoing ventricular cardiac dysrhythmias of National Cancer Institute (NCI) Common
             Terminology Criteria for Adverse Event (CTCAE) grade &gt;= 2

          -  Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia
             [VT] or ventricular fibrillation [VF] &gt;= 3 beats in a row)

          -  Serious cardiac arrhythmia requiring medication

          -  QTc interval &gt; 500 msec

          -  Psychiatric illness that would limit compliance with study requirements

          -  Pre-existing thyroid abnormality that cannot be maintained with medication to keep
             measures of thyroid stimulating hormone within the normal range

          -  Female subjects who are pregnant or breast-feeding

          -  Another severe and/or life-threatening medical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Deeken</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Associated Malignancies Clinical Trials Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS - Associated Malignancies Clinical Trials Consortium</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University - Jewish</name>
      <address>
        <city>Saint Loius</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.</citation>
    <PMID>24474568</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
    <mesh_term>Leukemia, Neutrophilic, Chronic</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

